Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778708 | 0.81 | FEN1 (0.53) | FEN1ALDH1A1HDAC8EGLN1 | |
| SCHEMBL4067804 | 0.78 | FEN1 (0.56) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL968338 | 0.76 | FEN1 (0.60) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL31304869 | 0.76 | FEN1 (0.60) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL1342390 | 0.74 | FEN1 (0.56) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL967939 | 0.74 | FEN1 (0.55) | FEN1ALDH1A1KDM4EL3MBTL1NPC1 | |
| SCHEMBL966559 | 0.74 | FEN1 (0.52) | FEN1ALDH1A1KDM4EEGLN1MAPT | |
| SCHEMBL967591 | 0.72 | FEN1 (0.47) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL967590 | 0.72 | FEN1 (0.47) | FEN1MMP2TSHRALDH1A1CHRM1 | |
| SCHEMBL4061458 | 0.71 | EGLN1 (0.65) | FEN1ALDH1A1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1622615-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | FEN1 489/4885MMP2 2484/4885TSHR 4218/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | FEN1 489/4885MMP2 2484/4885TSHR 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.